So grateful to Nazli Dizman Toni Choueiri, MD Ziad Bakouny, MD, MSc for the kind invitation. I've been amazed at the level of productivity from my postdoctoral fellows (all future IMG Oncologists) over the years. They ( #Dizman Zeynep Zengin Luis A. Meza Hedyeh Ebrahimi Regina Barragan-Carrillo

Congrats to the whole Stravin family, and to the team that makes these milestones possible! 🎉

Outstanding initiative from Neeraj Agarwal, MD, FASCO who is doing great stuff with the #ASCODailyNews ASCO #ASCO24 OncoAlert

Just in👉Our official ASCO #ASCODailyNews Podcast highlighting some GU abstracts from #ASCO24 👉 you can listen or read the transcript 👉Open access link to all across the world 👉 brnw.ch/21wK9q4 OncoAlert UroToday.com KidneyCAN PCF Science Bladder Cancer Advocacy Network

First Pan-Mass Challenge training ride. Amazing scenery! Only 25 miles but building up. Help us cure Cancer Dana-Farber

profile.pmc.org/TC0306

Team_More_Cowbell Marc Mombourquette Jeff Sulla

“Sell your cleverness and buy bewilderment. Cleverness is mere opinion. Bewilderment brings intuitive knowledge.”
Rumi, 13th century.

3 biomarker presentations in #kidneycancer from 2 mRCC trials (CLEAR/KYN426) with Brian Rini, MD Robert Motzer MD + an adjuvant trial w/ KIM-1 Laurence Albiges -Discussion by Wenxin (Vincent) Xu Dana-Farber Lank Center for Genitourinary Oncology Vincent is a rising star in #biomarkers + 1st to report on KIM1 in #RCC --Don't miss his

When used wisely, #ctDNA can be a powerful tool to guide therapy, especially in the adjuvant settings: still many shortcomings even with a bespoke assay: sensitivity, effectiveness of salvage therapy, and disease type matter a lot. Tom Powles Dana-Farber Lank Center for Genitourinary Oncology OncoAlert #ASCO24

Thanks Dana-Farber and Toni Choueiri, MD - another milestone in the books…4th and last college graduation. ✔️ Didn’t think this was possible when diagnosed back in 2015. Without you I don’t see this Proud Dad moment. THANK YOU!! 💜💜 The Jimmy Fund Dana-Farber_GU KidneyCAN

The network that continues to amaze !
OncoAlert with Gil Morgan, MD !

Our own joaquim bellmunt Dana-Farber Lank Center for Genitourinary Oncology making the the Neeraj Agarwal, MD, FASCO list for #ASCO24 ASCO

The work of Eddy Saad Eli Van Allen Sasha Gusev being highlighted here #ASCO24 ==> we again validate SNP in IL-7 to be associated with irAEs! Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber ASCO #Dana9team OncoAlert

Exactly Patxi Queipo !

There is quite some data on NECTIN4 prevalence in the different tumor entities, where EV is currently being developed in the biomarker-unselected setting

And single-agent activity of EV correlates quite well with overall NECTIN4 protein expression in

Pending #LBAs , my Top* 10 #ASCO24 (so far) are:

*list heavily GU-skewed

Dana-Farber ASCO

NANCY!!!!!!!!!!! Yeah!
Nancy Lin, MD Harvard Medical School Professor!
Dana-Farber Dana-FarberNews

Please join us for our 2nd annual meeting of the ASCO IMG Community of Practice!

We have a terrific agenda and lineup of speakers! #ASCO24

Ziad Bakouny, MD, MSc Nazli Dizman Neeraj Agarwal, MD, FASCO Noha N. Soror, MD, MSc. 𓂀 Tanios Bekaii-Saab, MD Narjust Florez, MD, FASCO Sumanta K. Pal, MD, FASCO Rafeh Naqash, MD OncoAlert IMG Oncologists

Ab#4508 ASCO #ASCO24 by Robert Motzer MD👉 tinyurl.com/yhk9457r 👉Final OS from JAVELIN Renal 101 ph3 trial #kidneycancer 👉 After ≥68 mos f-u, no OS benefit w/ avelumab/axitinib 👉making this regimen less optimal than other combinations👇 Toni Choueiri, MD OncoAlert UroToday.com

52% ORR in adrenal cancer ! Waiting for the presentation. Small numbers but quite intriguing! #ASCO24 ASCO OncoAlert Dana-Farber Lank Center for Genitourinary Oncology

The #ASCO24 abstracts are out:

tinyurl.com/4mj8nb73

I’m following Neeraj Agarwal, MD, FASCO for live updates !

ASCO Journal of Clinical Oncology OncoAlert

Very exciting! ASCO abstracts on phase EV-202 results have just been released:

Anti-NECTIN4 Enfortumab vedotin with disappointing efficacy in biomarker-unselected population beyond UC ASCO #ASCO24

Confirmed ORR in
- esophageal cancer 18.2%
- gastric cancer 9.5%
- NSCLC: